MedPath

Visual Outcomes After Cataract Surgery: Multifocal AcrySof® IQ ReSTOR® Intraocular Lenses Versus Monofocal Intraocular Lenses

Not Applicable
Completed
Conditions
Cataract
Interventions
Device: AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL
Device: Monofocal IOL
Device: AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL
Registration Number
NCT01290068
Lead Sponsor
Alcon Research
Brief Summary

The purpose of this study is to assess and compare visual outcomes of the AcrySof® IQ ReSTOR® +3.0 D intraocular lens (IOL) to a commercially available monofocal IOL in cataract patients.

Detailed Description

This study included subjects with bilateral age-related cataracts and either no preoperative corneal astigmatism, or preoperative regular corneal astigmatism confirmed by autokeratometry of ≤2.5 D.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
208
Inclusion Criteria
  • Willing and able to understand and sign an Informed Consent;
  • Willing and able to attend post-operative examinations as per protocol schedule;
  • Diagnosis of bilateral, age-related cataracts;
  • Planned cataract removal via phacoemulsification with implantation of an IOL;
  • Available to undergo second eye surgery within 6 weeks of the first eye surgery;
  • Fulfill the recommendations of the "Warnings" and "Precautions" sections of the AcrySof IQ ReSTOR IOL and Monofocal IOL package inserts;
  • No preoperative corneal astigmatism or preoperative regular corneal astigmatism ≤2.5D;
  • Qualify in both eyes for either AcrySof® IQ ReSTOR® IOL Model SN6AD1 or AcrySof® IQ ReSTOR® Toric IOL Models SND1T2 through SND1T5 as indicated by the AcrySof IQ ReSTOR Multifocal Toric web-based calculator;
  • Able to read and understand one of the following languages: Dutch, French, German, Italian, Spanish, English or Catalan.
  • Other protocol-defined inclusion criteria may apply.
Read More
Exclusion Criteria
  • Previous corneal surgery and/or reshaping;
  • Any abnormality, disease and/or conditions of the cornea (ie, keratoconus, corneal dystrophy, severe keratitis, corneal scar, etc.), which would clinically contraindicate the implantation of a toric IOL;
  • Planned multiple procedures during cataract/IOL implantation surgery;
  • Planned limbal relaxing incisions, excimer laser treatment or similar procedures prior to or during the course of the study;
  • Pregnant, lactating, or planning pregnancy during the course of study;
  • Other protocol-defined exclusion criteria may apply.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ReSTOR +3 ToricAcrySof® IQ ReSTOR® +3.0 D Multifocal IOLAcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative corneal astigmatism, bilateral implantation, or implanted in 1 eye with AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL in the other eye
ReSTOR +3AcrySof® IQ ReSTOR® +3.0 D Multifocal IOLAcrySof® IQ ReSTOR® +3.0 D Multifocal IOL, bilateral implantation
ReSTOR +3 ToricAcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOLAcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative corneal astigmatism, bilateral implantation, or implanted in 1 eye with AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL in the other eye
MonofocalMonofocal IOLMonofocal IOL, bilateral implantation
Primary Outcome Measures
NameTimeMethod
Proportion of Participants Reporting Spectacle Independence at All DistancesMonth 6 after second eye implantation

Spectacle independence at all distances; ie, where type of spectacles used/prescribed equaled 'No spectacles', was evaluated. If for the 6-month visit, spectacle type information was missing for the spectacle independence endpoint, but the subject attended this 6-month visit, subject was assumed to be spectacle independent.

Percentage of Participants Classified as RespondersMonth 6 after second eye implantation

Distance VA and near VA were measured binocularly (both eyes together) without visual correction using ETDRS (Early Treatment of Diabetic Retinopathy Study) charts positioned at a consistent, manufactured distance. VA was measured in logMAR (logarithm of the minimum angle of resolution), with a lower logMAR value indicating better visual acuity. A responder was defined as a participant who achieved bilateral uncorrected distance visual acuity and bilateral uncorrected near visual acuity of ≤0.1 LogMAR at the Month 6 visit.

Mean Vision-Related Quality of Life as Reported on the NEI-RQL 42 (5 Dimensions)Month 6 after second eye implantation

Vision-related quality of life dimensions were evaluated using the National Eye Institute Refractive Error Quality of Life instrument (NEI-RQL 42), a self-administered questionnaire. Each dimension was scored between 0 to 100, with a higher score indicating a better vision-related Quality of Life. 5 of the dimensions were prespecified as primary.

Secondary Outcome Measures
NameTimeMethod
Median Total Spectacle Cost Prior to Any ReimbursementMonth 6 after second eye implantation

Total spectacle cost includes the frame, lens, and any reimbursement from national health systems or private insurance. Costs collected in pounds sterling were converted to euros.

© Copyright 2025. All Rights Reserved by MedPath